PDF(Pubmed)
Abstract：
The Human T-lymphotropic virus type 1 (HTLV-1) was the first described human retrovirus. It is currently estimated that around 5 to 10 million people worldwide are infected with this virus. Despite its high prevalence, there is still no preventive vaccine against the HTLV-1 infection. It is known that vaccine development and large-scale immunization play an important role in global public health. To understand the advances in this field we performed a systematic review regarding the current progress in the development of a preventive vaccine against the HTLV-1 infection.
This review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA®) guidelines and was registered at the International Prospective Register of Systematic Reviews (PROSPERO). The search for articles was performed in PubMed, Lilacs, Embase and SciELO databases. From the 2,485 articles identified, 25 were selected according to the inclusion and exclusion criteria.
The analysis of these articles indicated that potential vaccine designs in development are available, although there is still a paucity of studies in the human clinical trial phase.
Although HTLV-1 was discovered almost 40 years ago, it remains a great challenge and a worldwide neglected threat. The scarcity of funding contributes decisively to the inconclusiveness of the vaccine development. The data summarized here intends to highlight the necessity to improve the current knowledge of this neglected retrovirus, encouraging for more studies on vaccine development aiming the to eliminate this human threat.
https://www.crd.york.ac.uk/prospero, identifier (CRD42021270412).
This review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA®) guidelines and was registered at the International Prospective Register of Systematic Reviews (PROSPERO). The search for articles was performed in PubMed, Lilacs, Embase and SciELO databases. From the 2,485 articles identified, 25 were selected according to the inclusion and exclusion criteria.
The analysis of these articles indicated that potential vaccine designs in development are available, although there is still a paucity of studies in the human clinical trial phase.
Although HTLV-1 was discovered almost 40 years ago, it remains a great challenge and a worldwide neglected threat. The scarcity of funding contributes decisively to the inconclusiveness of the vaccine development. The data summarized here intends to highlight the necessity to improve the current knowledge of this neglected retrovirus, encouraging for more studies on vaccine development aiming the to eliminate this human threat.
https://www.crd.york.ac.uk/prospero, identifier (CRD42021270412).
摘要：
未经证实：人类嗜T淋巴细胞病毒1型（HTLV-1）是第一个描述的人类逆转录病毒。据估计，目前全世界约有500万至1000万人感染了这种病毒。尽管流行率很高,目前尚无针对HTLV-1感染的预防性疫苗.众所周知，疫苗开发和大规模免疫在全球公共卫生中起着重要作用。为了了解该领域的进展，我们对针对HTLV-1感染的预防性疫苗的开发进展进行了系统评价。
UNASSIGNED：本审查遵循系统审查和荟萃分析的首选报告项目（PRISMA®）指南，并在国际前瞻性系统审查注册中心（PROSPERO）注册。文章的搜索是在PubMed中进行的，丁香花,Embase和SciELO数据库。从确定的2485篇文章中，根据纳入和排除标准选择25例。
UNASSIGNED：对这些文章的分析表明，正在开发的潜在疫苗设计是可用的，尽管人体临床试验阶段的研究仍然很少。
UNASSIGNED：尽管HTLV-1在40年前就被发现了，它仍然是一个巨大的挑战和全球被忽视的威胁。资金的匮乏决定性地导致了疫苗开发的不确定性。这里总结的数据旨在强调提高这种被忽视的逆转录病毒的当前知识的必要性，鼓励对旨在消除这种人类威胁的疫苗开发进行更多研究。
UNASSIGNED：https://www。crd.约克。AC.英国/普劳里,标识符(CRD42021270412)。
UNASSIGNED：本审查遵循系统审查和荟萃分析的首选报告项目（PRISMA®）指南，并在国际前瞻性系统审查注册中心（PROSPERO）注册。
UNASSIGNED：对这些文章的分析表明，正在开发的潜在疫苗设计是可用的，
UNASSIGNED：尽管HTLV-1在40年前就被发现了，
UNASSIGNED：https://www。
